Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences:

1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024.

2. 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024, where CEO Markus Warmuth, M.D., will participate in a fireside chat at 2:15 p.m. ET.

The fireside chat will be webcast and accessible through Monte Rosa's website, with an archived version available for 30 days after the presentation.

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

• Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) – September 4, 2024.
• 2024 Wells Fargo Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 5, 2024, at 2:15 p.m. ET.

A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.  

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When is Monte Rosa Therapeutics (GLUE) participating in the Morgan Stanley Healthcare Conference?

Monte Rosa Therapeutics (GLUE) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York, NY.

What is the date and time of Monte Rosa Therapeutics' (GLUE) fireside chat at the Wells Fargo Healthcare Conference?

Monte Rosa Therapeutics' (GLUE) CEO Markus Warmuth will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on September 5, 2024, at 2:15 p.m. ET in Boston, MA.

How can investors access Monte Rosa Therapeutics' (GLUE) fireside chat webcast?

Investors can access the webcast of Monte Rosa Therapeutics' (GLUE) fireside chat through the 'Events & Presentations' section of the company's website at ir.monterosatx.com.

What type of medicines is Monte Rosa Therapeutics (GLUE) developing?

Monte Rosa Therapeutics (GLUE) is developing novel molecular glue degrader (MGD)-based medicines.